Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromodomain helicase DNA binding protein 9 (CHD9) is an ATP-dependent chromatin remodeler and DNA helicase belonging to the CHD subfamily of SF2 helicase proteins. It binds to A/T-rich regulatory DNA regions, acts as a transcriptional coactivator for nuclear receptors (notably PPARA), and plays a role in the remodeling of chromatin structure, thereby regulating gene expression patterns and differentiation programs. Unlike several other CHD family members, CHD9 is not essential for mouse development but shows context- and cell-type-specific gene regulatory roles, influencing transcription, higher-order chromatin organization, and possibly disease states such as cancer and developmental syndromes linked to chromatin regulation[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromodomain helicase DNA binding protein 9 (CHD9).